Myeloid specific human CD33 is an inhibitory receptor with differential ITIM function in recruiting the phosphatases SHP-1 and SHP-2 - PubMed (original) (raw)
. 2000 Jul 15;96(2):483-90.
Affiliations
- PMID: 10887109
Free article
Myeloid specific human CD33 is an inhibitory receptor with differential ITIM function in recruiting the phosphatases SHP-1 and SHP-2
S P Paul et al. Blood. 2000.
Free article
Abstract
CD33 is a myeloid specific member of the sialic acid-binding receptor family and is expressed highly on myeloid progenitor cells but at much lower levels in differentiated cells. Human CD33 has two tyrosine residues in its cytoplasmic domain (Y340 and Y358). When phosphorylated, these tyrosines could function as docking sites for the phosphatases, SHP-1 and/or SHP-2, enabling CD33 to function as an inhibitory receptor. Here we demonstrate that CD33 is tyrosine phosphorylated in the presence of the phosphatase inhibitor, pervanadate, and recruits SHP-1 and SHP-2. Co-expression studies suggest that the Src-family kinase Lck is effective at phosphorylating Y340, but not Y358, suggesting that these residues may function in the selective recruitment of adapter molecules and have distinct functions. Further support for overlapping, but nonredundant, roles for Y340 and Y358 comes from peptide-binding studies that revealed the recruitment of both SHP-1 and SHP-2 to Y340 but only SHP-2 to Y358. Analysis using mutants of SHP-1 demonstrated that binding Y340 of CD33 was primarily to the amino Src homology-2 domain of SHP-1. The potential of CD33 to function as an inhibitory receptor was demonstrated by its ability to down-regulate CD64-induced calcium mobilization in U937. The dependence of this inhibition on SHP-1 was demonstrated by blocking CD33-mediated effects with dominant negative SHP-1. This result implies that CD33 is an inhibitory receptor and also that SHP-1 phosphatase has a significant role in mediating CD33 function. Further studies are essential to identify the receptor(s) that CD33 inhibits in vivo and its function in myeloid lineage development. (Blood. 2000;96:483-490)
Similar articles
- The myeloid-specific sialic acid-binding receptor, CD33, associates with the protein-tyrosine phosphatases, SHP-1 and SHP-2.
Taylor VC, Buckley CD, Douglas M, Cody AJ, Simmons DL, Freeman SD. Taylor VC, et al. J Biol Chem. 1999 Apr 23;274(17):11505-12. doi: 10.1074/jbc.274.17.11505. J Biol Chem. 1999. PMID: 10206955 - The sialoadhesin CD33 is a myeloid-specific inhibitory receptor.
Ulyanova T, Blasioli J, Woodford-Thomas TA, Thomas ML. Ulyanova T, et al. Eur J Immunol. 1999 Nov;29(11):3440-9. doi: 10.1002/(SICI)1521-4141(199911)29:11<3440::AID-IMMU3440>3.0.CO;2-C. Eur J Immunol. 1999. PMID: 10556798 - Cytoplasmic protein tyrosine phosphatases SHP-1 and SHP-2: regulators of B cell signal transduction.
Tamir I, Dal Porto JM, Cambier JC. Tamir I, et al. Curr Opin Immunol. 2000 Jun;12(3):307-15. doi: 10.1016/s0952-7915(00)00092-3. Curr Opin Immunol. 2000. PMID: 10781410 Review. - Inhibitory receptors abound?
Cambier JC. Cambier JC. Proc Natl Acad Sci U S A. 1997 Jun 10;94(12):5993-5. doi: 10.1073/pnas.94.12.5993. Proc Natl Acad Sci U S A. 1997. PMID: 9177155 Free PMC article. Review. No abstract available.
Cited by
- CD33 and SHP-1/PTPN6 Interaction in Alzheimer's Disease.
Beckers L, Rashid M, Lee AJ, Chatila ZK, Tamucci KA, Talcoff RC, Hall JL, Bennett DA, Vardarajan BN, Bradshaw EM. Beckers L, et al. Genes (Basel). 2024 Sep 13;15(9):1204. doi: 10.3390/genes15091204. Genes (Basel). 2024. PMID: 39336795 Free PMC article. - Antibody-drug conjugates in cancer therapy: mechanisms and clinical studies.
He J, Zeng X, Wang C, Wang E, Li Y. He J, et al. MedComm (2020). 2024 Jul 28;5(8):e671. doi: 10.1002/mco2.671. eCollection 2024 Aug. MedComm (2020). 2024. PMID: 39070179 Free PMC article. Review. - Dissecting the Ability of Siglecs To Antagonize Fcγ Receptors.
McCord KA, Wang C, Anhalt M, Poon WW, Gavin AL, Wu P, Macauley MS. McCord KA, et al. ACS Cent Sci. 2024 Jan 17;10(2):315-330. doi: 10.1021/acscentsci.3c00969. eCollection 2024 Feb 28. ACS Cent Sci. 2024. PMID: 38435516 Free PMC article. - HuM195 and its single-chain variable fragment increase Aβ phagocytosis in microglia via elimination of CD33 inhibitory signaling.
Wong E, Malviya M, Jain T, Liao GP, Kehs Z, Chang JC, Studer L, Scheinberg DA, Li YM. Wong E, et al. Mol Psychiatry. 2024 Jul;29(7):2084-2094. doi: 10.1038/s41380-024-02474-z. Epub 2024 Feb 21. Mol Psychiatry. 2024. PMID: 38383769 - Transient TKI-resistant CD44+pBAD+ blasts undergo intrinsic homeostatic adaptation to promote the survival of acute myeloid leukemia in vitro.
Xu Y, Baylink DJ, Chen CS, Tan L, Xiao J, Park B, Valladares I, Reeves ME, Cao H. Xu Y, et al. Front Oncol. 2023 Nov 8;13:1286863. doi: 10.3389/fonc.2023.1286863. eCollection 2023. Front Oncol. 2023. PMID: 38023123 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Miscellaneous